留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HIV阳性肾移植研究进展

韩飞, 黄正宇. HIV阳性肾移植研究进展[J]. 器官移植, 2022, 13(4): 434-439. doi: 10.3969/j.issn.1674-7445.2022.04.004
引用本文: 韩飞, 黄正宇. HIV阳性肾移植研究进展[J]. 器官移植, 2022, 13(4): 434-439. doi: 10.3969/j.issn.1674-7445.2022.04.004
Han Fei, Huang Zhengyu. Research progress on kidney transplantation in HIV-positive patients[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 434-439. doi: 10.3969/j.issn.1674-7445.2022.04.004
Citation: Han Fei, Huang Zhengyu. Research progress on kidney transplantation in HIV-positive patients[J]. ORGAN TRANSPLANTATION, 2022, 13(4): 434-439. doi: 10.3969/j.issn.1674-7445.2022.04.004

HIV阳性肾移植研究进展

doi: 10.3969/j.issn.1674-7445.2022.04.004
基金项目: 

国家自然科学基金 81970649

中国博士后科学基金 2020M683083

详细信息
    作者简介:
    通讯作者:

    黄正宇,Email: hzhengy@mail.sysu.edu.cn

  • 中图分类号: R617, R512.91

Research progress on kidney transplantation in HIV-positive patients

More Information
  • 摘要: 人类免疫缺陷病毒(HIV)感染者容易出现肾功能不全,并可进展至终末期肾病(ESRD)。既往HIV阳性被认为是移植的绝对禁忌证,HIV阳性ESRD患者只能通过透析维持生命。随着医学的发展,国内外移植工作者尝试对HIV阳性患者进行肾移植。HIV阳性患者是否可接受肾移植,是否可以使用HIV阳性供肾进行移植,HIV阳性患者肾移植的效果如何也一直是移植界探讨的热点。本文就HIV相关性肾病、HIV阳性患者接受肾移植的条件、HIV阳性患者接受肾移植的效果、HIV阳性供肾的使用、HIV阳性患者免疫诱导药与术后免疫抑制药的使用进行探讨,以期为临床HIV阳性患者的肾移植、HIV阳性供肾的应用及HIV阳性患者肾移植术后的管理提供参考。

     

  • [1] Global HIV & AIDS statistics[EB/OL]. [2022-01-01]. https://aidsinfo.unaids.org/
    [2] YANG HY, BEYMER MR, SUEN SC. Chronic disease onset among people living with HIV and AIDS in a large private insurance claims dataset[J]. Sci Rep, 2019, 9(1): 18514. DOI: 10.1038/s41598-019-54969-3.
    [3] JOHNSON LF, ANDEREGG N, ZANIEWSKI E, et al. Global variations in mortality in adults after initiating antiretroviral treatment: an updated analysis of the International epidemiology Databases to Evaluate AIDS cohort collaboration[J]. AIDS, 2019, 33(Suppl 3): S283-S294. DOI: 10.1097/QAD.0000000000002358.
    [4] WEARNE N, HUNG R, BOHMER R, et al. Kidney disease in Africans with HIV and tuberculosis[J]. AIDS, 2019, 33(7): 1207-1213. DOI: 10.1097/QAD.0000000000002204.
    [5] KUMAR MS, SIERKA DR, DAMASK AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients[J]. Kidney Int, 2005, 67(4): 1622-1629. DOI: 10.1111/j.1523-1755.2005.00245.x.
    [6] PIERROTTI LC, LITVINOV N, COSTA SF, et al. A Brazilian university hospital position regarding transplantation criteria for HIV-positive patients according to the current literature[J]. Clinics (Sao Paulo), 2019, 74: e941. DOI: 10.6061/clinics/2019/e941.
    [7] MULLER E, BOTHA FCJ, BARDAY ZA, et al. Kidney transplantation in HIV-positive patients: current practice and management strategies[J]. Transplantation, 2021, 105(7): 1492-1501. DOI: 10.1097/TP.0000000000003485.
    [8] TARIQ A, KIM H, ABBAS H, et al. Pharmacotherapeutic options for kidney disease in HIV positive patients[J]. Expert Opin Pharmacother, 2021, 22(1): 69-82. DOI: 10.1080/14656566.2020.1817383.
    [9] YUSUF AA, MUSA BM, GALADANCI NA, et al. HIV-associated nephropathy: protocol and rationale for an exploratory genotype-phenotype study in a sub-Saharan African population[J]. PLoS One, 2021, 16(4): e0249567. DOI: 10.1371/journal.pone.0249567.
    [10] KOPP JB, WINKLER C. HIV-associated nephropathy in African Americans[J]. Kidney Int Suppl, 2003(83): S43- S49. DOI: 10.1046/j.1523-1755.63.s83.10.x.
    [11] GOYAL R, SINGHAL PC. APOL1 risk variants and the development of HIV-associated nephropathy[J]. FEBS J, 2021, 288(19): 5586-5597. DOI: 10.1111/febs.15677.
    [12] BEHAR DM, KEDEM E, ROSSET S, et al. Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population[J]. Am J Nephrol, 2011, 34(5): 452-459. DOI: 10.1159/000332378.
    [13] DUMMER PD, LIMOU S, ROSENBERG AZ, et al. APOL1 kidney disease risk variants: an evolving landscape[J]. Semin Nephrol, 2015, 35(3): 222-236. DOI: 10.1016/j.semnephrol.2015.04.008.
    [14] SANTIPRABHOB J, CHOKEPHAIBULKIT K, KHANTEE P, et al. Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors[J]. Cytokine, 2020, 136: 155145. DOI: 10.1016/j.cyto.2020.155145.
    [15] NON LR, ESCOTA GV, POWDERLY WG. HIV and its relationship to insulin resistance and lipid abnormalities[J]. Transl Res, 2017, 183: 41-56. DOI: 10.1016/j.trsl.2016.12.007.
    [16] SARMA A, DAS MK. Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS[J]. Mol Biomed, 2020, 1(1): 15. DOI: 10.1186/s43556-020-00019-8.
    [17] PRETORIUS E. Platelets in HIV: a guardian of host defence or transient reservoir of the virus?[J]. Front Immunol, 2021, 12: 649465. DOI: 10.3389/fimmu.2021.649465.
    [18] MEHRBOD P, ANDE SR, ALIZADEH J, et al. The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections[J]. Virulence, 2019, 10(1): 376-413. DOI: 10.1080/21505594.2019.1605803.
    [19] SNYDER A, ALSAUSKAS ZC, LEVENTHAL JS, et al. HIV-1 viral protein R induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells[J]. AIDS, 2010, 24(8): 1107-1119. DOI: 10.1097/QAD.0b013e328337b0ab.
    [20] ROSENSTIEL PE, GRUOSSO T, LETOURNEAU AM, et al. HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells[J]. Kidney Int, 2008, 74(8): 1049-1058. DOI: 10.1038/ki.2008.303.
    [21] LI J, DAS JR, TANG P, et al. Transmembrane TNF-α facilitates HIV-1 infection of podocytes cultured from children with HIV-associated nephropathy[J]. J Am Soc Nephrol, 2017, 28(3): 862-875. DOI: 10.1681/ASN.2016050564.
    [22] TANJI N, ROSS MD, TANJI K, et al. Detection and localization of HIV-1 DNA in renal tissues by in situ polymerase chain reaction[J]. Histol Histopathol, 2006, 21(4): 393-401. DOI: 10.14670/HH-21.393.
    [23] CANAUD G, DEJUCQ-RAINSFORD N, AVETTAND-FENOËL V, et al. The kidney as a reservoir for HIV-1 after renal transplantation[J]. J Am Soc Nephrol, 2014, 25(2): 407-419. DOI: 10.1681/ASN.2013050564.
    [24] GILBERT J, MANJI A. Considerations in the management of a kidney transplant patient with HIV[J]. Cureus, 2021, 13(10): e18744. DOI: 10.7759/cureus.18744.
    [25] ALAMEDDINE M, JUE JS, ZHENG I, et al. Challenges of kidney transplantation in HIV positive recipients[J]. Transl Androl Urol, 2019, 8(2): 148-154. DOI: 10.21037/tau.2018.11.09.
    [26] MIRO JM, GROSSI PA, DURAND CM. Challenges in solid organ transplantation in people living with HIV[J]. Intensive Care Med, 2019, 45(3): 398-400. DOI: 10.1007/s00134-019-05524-1.
    [27] TRULLAS JC, COFAN F, TUSET M, et al. Renal transplantation in HIV-infected patients: 2010 update[J]. Kidney Int, 2011, 79(8): 825-842. DOI: 10.1038/ki.2010.545.
    [28] ROLAND ME, BARIN B, CARLSON L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes[J]. Am J Transplant, 2008, 8(2): 355-365. DOI: 10.1111/j.1600-6143.2007.02061.x.
    [29] STOCK PG, BARIN B, MURPHY B, et al. Outcomes of kidney transplantation in HIV-infected recipients[J]. N Engl J Med, 2010, 363(21): 2004-2014. DOI: 10.1056/NEJMoa1001197.
    [30] CHEN P, CHEN BK, MOSOIAN A, et al. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells[J]. J Am Soc Nephrol, 2011, 22(3): 496-507. DOI: 10.1681/ASN.2010040379.
    [31] MULLER E, KAHN D, MENDELSON M. Renal transplantation between HIV-positive donors and recipients[J]. N Engl J Med, 2010, 362(24): 2336-2337. DOI: 10.1056/NEJMc0900837.
    [32] CHOW EK, MASSIE AB, MUZAALE AD, et al. Identifying appropriate recipients for CDC infectious risk donor kidneys[J]. Am J Transplant, 2013, 13(5): 1227-1234. DOI: 10.1111/ajt.12206.
    [33] KUCIRKA LM, ROS RL, SUBRAMANIAN AK, et al. Provider response to a rare but highly publicized transmission of HIV through solid organ transplantation[J]. Arch Surg, 2011, 146(1): 41-45. DOI: 10.1001/archsurg.2010.303.
    [34] ROS RL, KUCIRKA LM, GOVINDAN P, et al. Patient attitudes toward CDC high infectious risk donor kidney transplantation: inferences from focus groups[J]. Clin Transplant, 2012, 26(2): 247-253. DOI: 10.1111/j.1399-0012.2011.01469.x.
    [35] SCHWEITZER EJ, PERENCEVICH EN, PHILOSOPHE B, et al. Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection[J]. Am J Transplant, 2007, 7(6): 1515-1525. DOI: 10.1111/j.1600-6143.2007.01769.x.
    [36] BOWRING MG, HOLSCHER CM, ZHOU S, et al. Turn down for what? patient outcomes associated with declining increased infectious risk kidneys[J]. Am J Transplant, 2018, 18(3): 617-624. DOI: 10.1111/ajt.14577.
    [37] LOCKE JE, JAMES NT, MANNON RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients[J]. Transplantation, 2014, 97(4): 446-450. DOI: 10.1097/01.TP.0000436905.54640.8c.
    [38] EL SAKHAWI K, MELICA G, SCEMLA A, et al. Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients[J]. Clin Kidney J, 2020, 14(8): 1908-1914. DOI: 10.1093/ckj/sfaa231.
  • 加载中
图(1)
计量
  • 文章访问数:  293
  • HTML全文浏览量:  129
  • PDF下载量:  79
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-30
  • 网络出版日期:  2022-07-14
  • 刊出日期:  2022-07-15

目录

    /

    返回文章
    返回